Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN: Long-Term Safety and Efficacy of Peginterferon Beta-1a in Relapsing MS
NCT01332019Phase 3Completed
- Sponsor
- Biogen
- Start
- Apr 2011
- Primary completion
- Oct 2015
- Modality
- Cytokines & Interferons
- Countries
- 26
01
Overview
A Phase 3 trial of peginterferon beta-1a in multiple sclerosis (MS), sponsored by Biogen. Started Apr 2011; status: completed.
02
Drugs
peginterferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01332019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01332019.